PRMT1 mediated methylation of cGAS suppresses anti-tumor immunity

• Published in: Nature communications Vol. 14; no. 1; pp. 2806 - 15
• Main Authors: Liu, Jing, Bu, Xia, Chu, Chen, Dai, Xiaoming, Asara, John M., Sicinski, Piotr, Freeman, Gordon J., Wei, Wenyi
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 17.05.2023; Nature Publishing Group; Nature Portfolio
• Subjects: 13/1; 13/106; 13/109; 13/31; 13/95; 38/88; 38/91; 631/250/262/2106; 631/67/1059/2325; 631/67/580/1884; 631/80/458/1648; 64; 64/60; 82/58; 82/83; 96; 96/63; Ablation; Antibodies; Anticancer properties; B7-H1 Antigen - genetics; B7-H1 Antigen - metabolism; Dimerization; Effectiveness; Humanities and Social Sciences; Immune response; Immune system; Immunity; Immunity, Innate - genetics; Immunosurveillance; Immunotherapy; In vivo methods and tests; Innate immunity; Lymphocytes; Methylation; Methyltransferases - metabolism; multidisciplinary; Nucleotidyltransferases - metabolism; PD-1 protein; PD-L1 protein; Protein arginine methyltransferase; Science; Science (multidisciplinary); Signal Transduction - genetics; Signaling; Surveillance; Therapeutic targets; Tumor-infiltrating lymphocytes; Tumorigenesis; Tumors
• ISSN: 2041-1723; 2041-1723
• DOI: 10.1038/s41467-023-38443-3

Activation of the cGAS/STING innate immunity pathway is essential and effective for anti-tumor immunotherapy. However, it remains largely elusive how tumor-intrinsic cGAS signaling is suppressed to facilitate tumorigenesis by escaping immune surveillance. Here, we report that the protein arginine methyltransferase, PRMT1, methylates cGAS at the conserved Arg133 residue, which prevents cGAS dimerization and suppresses the cGAS/STING signaling in cancer cells. Notably, genetic or pharmaceutical ablation of PRMT1 leads to activation of cGAS/STING-dependent DNA sensing signaling, and robustly elevates the transcription of type I and II interferon response genes. As such, PRMT1 inhibition elevates tumor-infiltrating lymphocytes in a cGAS-dependent manner, and promotes tumoral PD-L1 expression. Thus, combination therapy of PRMT1 inhibitor with anti-PD-1 antibody augments the anti-tumor therapeutic efficacy in vivo. Our study therefore defines the PRMT1/cGAS/PD-L1 regulatory axis as a critical factor in determining immune surveillance efficacy, which serves as a promising therapeutic target for boosting tumor immunity. cGAS/STING mediated immunity is linked to the anti-tumor response, but how tumor-intrinsic cGAS signals are countered during tumorigenesis and immune evasion is poorly understood. Here the authors show PRMT1 suppresses the anti-tumor immune response via arginine methylation of cGAS.